ES2422263T3 - Pirazoles bicíclicos como inhibidores de la proteinquinasa - Google Patents
Pirazoles bicíclicos como inhibidores de la proteinquinasaInfo
- Publication number
- ES2422263T3 ES2422263T3 ES09775222T ES09775222T ES2422263T3 ES 2422263 T3 ES2422263 T3 ES 2422263T3 ES 09775222 T ES09775222 T ES 09775222T ES 09775222 T ES09775222 T ES 09775222T ES 2422263 T3 ES2422263 T3 ES 2422263T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- heteroaryl
- optionally substituted
- group selected
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto de fórmula (I):**Fórmula** en donde: X es CH o N; R1 es hidrógeno, halógeno, NR7R8, NHCOR9, SR10 o SO2R, en donde: R7 y R8 son, independientemente uno de otro, hidrógeno, o un grupo opcionalmentesustituido seleccionado entre alquilo (C1-C8) alquilo lineal o ramificado, cicloalquilo (C3-C8), heterociclilo, arilo y heteroarilo, o R7 y R8 tomados juntos pueden formar un grupoftalilo, R9 es OR10, NR11R12 o un grupo opcionalmente sustituido seleccionado de alquilo (C1-C8) alquilo lineal o ramificado, alquenilo (C2-C8) o alquenilo (C2-C8), cicloalquilo (C3-C8),heterociclilo, arilo y heteroarilo, R10 es un grupo opcionalmente sustituido seleccionado entre alquilo (C1-C8) lineal oramificado, cicloalquilo (C3-C8), heterociclilo, arilo y heteroarilo, R11 y R12 son, independientemente uno de otro, hidrógeno o un grupo opcionalmentesustituido seleccionado de alquilo (C1-C8) lineal o ramificado, cicloalquilo (C3-C8),heterociclilo, arilo y heteroarilo, o tomados junto con el átomo de nitrógeno al cual estánunidos R11 y R12 pueden formar un heterociclilo o heteroarilo de 3 a 8 miembrosopcionalmente sustituido, que contiene opcionalmente un heteroátomo o grupoheteroatómico adicional seleccionado entre S, O, N o NH.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08172429 | 2008-12-19 | ||
PCT/EP2009/067438 WO2010070060A1 (en) | 2008-12-19 | 2009-12-17 | Bicyclic pyrazoles as protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2422263T3 true ES2422263T3 (es) | 2013-09-10 |
Family
ID=41565939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES09775222T Active ES2422263T3 (es) | 2008-12-19 | 2009-12-17 | Pirazoles bicíclicos como inhibidores de la proteinquinasa |
Country Status (5)
Country | Link |
---|---|
US (1) | US8524707B2 (es) |
EP (1) | EP2373664B1 (es) |
JP (1) | JP5490137B2 (es) |
ES (1) | ES2422263T3 (es) |
WO (1) | WO2010070060A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
EP2402339A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
CA2877474A1 (en) * | 2011-06-20 | 2012-12-27 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
BR112014008223A2 (pt) * | 2011-10-06 | 2017-04-25 | Bayer Ip Gmbh | heterociclilpiri (mi) dinilpirazol |
CN108542906A (zh) | 2011-11-11 | 2018-09-18 | 诺华股份有限公司 | 治疗增生性疾病的方法 |
SG11201401260QA (en) | 2011-11-23 | 2014-07-30 | Novartis Ag | Pharmaceutical formulations |
TWI679205B (zh) * | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | 吡唑并噻唑化合物及醫藥 |
TWI712604B (zh) * | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | 具jak抑制作用之化合物之結晶 |
CN106883266B (zh) * | 2017-01-23 | 2020-03-17 | 江苏七洲绿色化工股份有限公司 | 一种1-(4-氯苯基)-2-环丙基-1-丙酮的制备方法及其中间体 |
MX2023008589A (es) * | 2021-01-22 | 2023-08-09 | Hibercell Inc | Compuestos moduladores de gcn2 y usos de los mismos. |
WO2023091873A1 (en) * | 2021-11-19 | 2023-05-25 | The Board Of Trustees Of The University Of Illinois | Gram-negative specific antibiotics sparing effect on gut microbiome |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD103006A1 (es) | 1972-12-29 | 1974-01-05 | ||
DD157803A1 (de) | 1980-03-20 | 1982-12-08 | Klaus Peseke | Verfahren zur herstellung von pyrazolo[5.1-b][1.3]thiazinen |
JPS6438091A (en) * | 1986-03-20 | 1989-02-08 | Takeda Chemical Industries Ltd | Condensed heterocyclic sulfonylurea |
JP3383813B2 (ja) | 1992-01-29 | 2003-03-10 | ミシシツピー・ステイト・ユニバーシテイ・リサーチ・アンド・テクノロジー・コーポレーシヨン | 置換されたフェニル複素環式除草剤 |
MXPA03001189A (es) * | 2000-08-09 | 2004-05-14 | Agouron Pharma | Compuestos de pirazol-tiazol, composiciones farmaceuticas que los contienen y su uso para inhibir las cinasas dependientes de ciclinas. |
CN100436452C (zh) * | 2000-12-21 | 2008-11-26 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的吡唑化合物 |
ATE274515T1 (de) * | 2001-03-08 | 2004-09-15 | Smithkline Beecham Corp | Pyrazolopyridinderivate |
DK1397364T3 (da) * | 2001-05-24 | 2007-11-26 | Lilly Co Eli | Hidtil ukendte pyrrolderivater som farmaceutiske midler |
WO2006068826A2 (en) * | 2004-12-21 | 2006-06-29 | Smithkline Beecham Corporation | 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors |
WO2007059341A2 (en) | 2005-11-16 | 2007-05-24 | Sgx Pharmaceuticals, Inc. | Pyrazolothiazole protein kinase modulators |
WO2007105058A2 (en) * | 2006-03-16 | 2007-09-20 | Pfizer Products Inc. | Pyrazole compounds |
EP2013218A2 (en) * | 2006-04-17 | 2009-01-14 | Arqule, Inc. | Raf inhibitors and their uses |
FR2904626B1 (fr) | 2006-08-03 | 2008-09-19 | Sanofi Aventis | Derives de pyrazolo[4,3]thiazole, leur preparation et leur application en therapeutique |
-
2009
- 2009-12-17 ES ES09775222T patent/ES2422263T3/es active Active
- 2009-12-17 US US13/140,915 patent/US8524707B2/en active Active
- 2009-12-17 EP EP09775222.4A patent/EP2373664B1/en active Active
- 2009-12-17 WO PCT/EP2009/067438 patent/WO2010070060A1/en active Application Filing
- 2009-12-17 JP JP2011541448A patent/JP5490137B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2012512837A (ja) | 2012-06-07 |
JP5490137B2 (ja) | 2014-05-14 |
EP2373664B1 (en) | 2013-06-12 |
EP2373664A1 (en) | 2011-10-12 |
WO2010070060A1 (en) | 2010-06-24 |
US20110257165A1 (en) | 2011-10-20 |
US8524707B2 (en) | 2013-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2422263T3 (es) | Pirazoles bicíclicos como inhibidores de la proteinquinasa | |
CO6231035A2 (es) | Novedoso compuesto heteromonociclico que tiene propiedades superiores como agente farmaceutico | |
CO6300866A2 (es) | Derivado de imidazopiridin - 2 - on | |
CO2017003132A2 (es) | Inhibidores de la aldosterona sintasa derivados de la 2,6-diazaspiro[3.3]heptán-6-il]-3-piridil]isoindolín-1-ona o 2,7-diazaspiro[3.5]nonán-2-il]-3-piridil]isoindolín-1-ona | |
ES2770058T3 (es) | Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante | |
AR058404A1 (es) | Derivados diamina como inhibidores de leucotrieno a4 hidrolasa | |
CO6210724A2 (es) | Compuesto heterociclico y composicion farmaceutica del mismo | |
CO6321130A2 (es) | Piridinas carboxamidas como inhibidores de la 11 beta-hsd1 | |
ES2590504T3 (es) | N-ciclilamidas como nematicidas | |
BR112012018412A2 (pt) | isoquinolinonas e quinazolinonas substituídas | |
AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
CO6220966A2 (es) | Derivados de piridazinona utiles como inhibidores de glucano sintasa | |
AR067838A1 (es) | Compuestos pirrolicos, composiciones farmaceuticas que los contienen y usos | |
AR072016A1 (es) | Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato | |
AR082029A1 (es) | Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt | |
CY1114067T1 (el) | Παραγωγα πυρρολιδιν-2-ονης ως ρυθμιστες υποδοχεα ανδρογονων | |
AR087467A1 (es) | Compuesto heterociclico fusionado y su uso para el control de plagas | |
PE20090905A1 (es) | Compuestos heterociclicos de amidas como inhibidores de la proteincinasa | |
UY39338A (es) | Derivados de piperidinona como inhibidores mdm2, composiciones farmacéuticas que los contienen y sus usos | |
CO6321166A2 (es) | Compuestos de pirrol | |
ES2531274T3 (es) | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas | |
CO6140056A2 (es) | Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa | |
CO5700818A2 (es) | Derivados de oxazol de tetraciclina | |
ECSP055987A (es) | Derivados de heteroarilcarbamoilbenceno | |
AR080187A1 (es) | Derivados pirazolicos condensados con heterociclos nitrogenados utiles en el tratamiento de enfermedades inflamatorias, inmunitarias y/o trastornos mieloploliferativos y composiciones farmaceuticas que los contienen. |